New cancer drug BBO-10203 enters first human trials

NCT ID NCT06625775

Recruiting now Disease control Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safety, side effects, and the best dose, both alone and combined with other cancer drugs. About 392 participants will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BBO-10203 (a drug that targets PI3K and RAS proteins)
What this could lead to: If successful, this could lead to a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early (Phase 1) study, so the drug may not be safe or effective. Side effects are unknown, and it may not work for all cancer types tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm colorectal cancer colorectal neoplasm HER2 positive breast carcinoma hormone receptor-positive breast cancer lung cancer lung carcinoma lung neoplasm metastatic malignant neoplasm Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER ADVANCED LUNG CANCER HER2 MUTATION-RELATED TUMORS HER2-POSITIVE ADVANCED BREAST CANCER HER2-POSITIVE METASTATIC BREAST CANCER HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER KRAS MUTANT METASTATIC COLORECTAL CANCER METASTATIC BREAST CANCER METASTATIC COLORECTAL CANCER METASTATIC LUNG CANCER SOLID TUMOR, ADULT

Contacts and locations

Locations

Centre Léon Bérard
RECRUITING

Lyon, 69008, France
City of Hope Comprehensive Cancer Center
RECRUITING

Duarte, California, 91010, United States
Clinica de Pesquisas e Centro de Estudos Em Oncologia Ginecologica e Mamaria Ltda
RECRUITING

São Paulo, São Paulo, 01317, Brazil
Columbia University Irving Medical Center
RECRUITING

New York, New York, 10032, United States
Dana-Farber Cancer Insitute
RECRUITING

Boston, Massachusetts, 02215, United States
FUTTURA Oncologia
RECRUITING

Porto Alegre, Rio Grande do Sul, 90470, Brazil
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Hospital Beata Maria Ana
RECRUITING

Madrid, Madrid, 28007, Spain
Hospital Quiron Madrid - NEXT Oncology
RECRUITING

Pozuelo de Alarcón, Madrid, 28223, Spain
Hospital São Lucas da PUCRS
RECRUITING

Porto Alegre, Rio Grande do Sul, 90610, Brazil
Hospital Universitari Arnau de Vilanova
RECRUITING

Lleida, 25198, Spain
Hospital Universitari i Politècnic La Fe
RECRUITING

Valencia, 46026, Spain
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, 28041, Spain
Hospital Universitario Fundación Jiménez Díaz
RECRUITING

Madrid, 28040, Spain
Hospital Universitario Vall d'Hebron
RECRUITING

Barcelona, Catalonia, 08035, Spain
IEPE - Unimed Sorocaba
RECRUITING

Sorocaba, São Paulo, 18056, Brazil
IOB Institute of Oncology - Hospital Quironsalud Barcelona
RECRUITING

Barcelona, 08023, Spain
Indiana University Simon Comprehensive Cancer Center
RECRUITING

Indianapolis, Indiana, 46202, United States
Institut Bergonie
RECRUITING

Bordeaux, 33000, France
Institut Curie - René-Huguenin Hospital
RECRUITING

Saint-Cloud, Paris, 92210, France
Institut Gustave Roussy
RECRUITING

Villejuif, Île-de-France Region, 94805, France
Institut régional du Cancer de Montpellier - Val d'Aurelle
RECRUITING

Montpellier, Occitanie, 34298, France
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Peter MacCallum Cancer Centre
RECRUITING

Melbourne, Victoria, 3000, Australia
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
SCRI at Mary Crowley
RECRUITING

Dallas, Texas, 75230, United States
START Barcelona - HM Nou Delfos Hospital
RECRUITING

Barcelona, 08023, Spain
Scientia Clinical Research
RECRUITING

Randwick, New South Wales, 2031, Australia
St. Lukes Hospital of Kansas City
RECRUITING

Kansas City, Missouri, 64111, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
UCSF Helen Diller Family Comprehensive Cancer Center
RECRUITING

San Francisco, California, 94158, United States
University of California Los Angeles
RECRUITING

Los Angeles, California, 90095, United States
University of California San Diego Moores Cancer Center
RECRUITING

San Diego, California, 92093, United States
University of Texas San Antonio (UTSA)
RECRUITING

San Antonio, Texas, 78229, United States
University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States
Wisconsin Institute for Medical Research
RECRUITING

Madison, Wisconsin, 53792, United States
lnstitut de Cancérologie de l'Ouest - Site Saint-Herblain
RECRUITING

Saint-Herblain, Pays de la Loire Region, 44805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.